Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- solid plates prostaglandins measures kits eias enzyme immunoassays ELISAs eyes ophthalmology ophthalmological intraocular glaucoma esters FP receptors agonists phxa85 17-phenyl-13,14-dihydro-trinor-PGF2alpha 17-phenyl-13,14-dihydro-trinor-PGF2.alpha. assays
- Product Overview:
Latanoprost is 13,14-dihydro-17-phenyl-18,19,20-trinor prostaglandin F2? isopropyl ester (13,14-dihydro-17-phenyl-18,19,20-trinor PGF2? isopropyl ester), an F-series prostaglandin analog which has been approved for use as an ocular hypotensive drug.{1107,8322,3802} Prostaglandin esters and other similar derivatives act as prodrugs which are converted to the active free acid form by an esterase/amidase activity in ocular tissues. The free acid form of Latanoprost (Latanoprost free acid (Lat-FA), or PhXA 85) is 200 times more potent than the isopropyl ester as an FP receptor ligand tested using the recombinant human FP receptor.{8322} Although the exact mechanism of the intraocular hypotensive effect of prostaglandins is unknown, it correlates very closely with the FP receptor ligand binding affinity of FP receptor agonists.{3310} The Cayman Latanoprost ELISA is a sensitive detection method for measuring the free acid form of Latanoprost. It also detects the isopropyl ester form of Latanoprost, but with less sensitivity. The assay is most appropriate for use when only one of the two forms is present. Samples containing mixtures of both the isopropyl ester and free acid should be purified and the two compounds separated prior to ELISA analysis.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.